DescriptionSources: http://labeling.pfizer.com/ShowLabeling.aspx?id=4617Curator's Comment: Description was created based on several sources, including
https://www.brambleberry.com/sodium-lactate-p5127.aspx | http://www.fbcindustries.com/Sodium_Lactate.aspx
Sources: http://labeling.pfizer.com/ShowLabeling.aspx?id=4617
Curator's Comment: Description was created based on several sources, including
https://www.brambleberry.com/sodium-lactate-p5127.aspx | http://www.fbcindustries.com/Sodium_Lactate.aspx
Sodium lactate is primarily indicated as a source of bicarbonate for prevention or control of mild to moderate metabolic acidosis in patients
with restricted oral intake whose oxidative processes are not seriously impaired. Sodium Lactate is most commonly associated with an E number of “E325” Sodium Lactate blends are commonly used in meat and poultry products to extend shelf life and increase food safety. They have a broad antimicrobial action and are effective at inhibiting most spoilage and pathogenic bacteria. In addition sodium lactate is used in cosmetics as a humectant, providing moisture.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10904049 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SODIUM LACTATE IN PLASTIC CONTAINER Approved UseSodium Lactate Injection, USP 50 mEq (5 mEq/mL), is primarily indicated, after dilution, as a source of bicarbonate for prevention or control of mild to moderate metabolic acidosis in patients with restricted oral intake whose oxidative processes are not seriously impaired. It is not intended nor effective for correcting severe acidotic states which require immediate restoration of plasma bicarbonate levels. Sodium lactate has no advantage over sodium bicarbonate and may be detrimental in the management of lactic acidosis Launch Date1984 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15236001/ |
39.76 mmol other, intravenous dose: 39.76 mmol route of administration: Intravenous experiment type: OTHER co-administered: |
LACTATE ION, L- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.03 mg/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15236001/ |
39.76 mmol other, intravenous dose: 39.76 mmol route of administration: Intravenous experiment type: OTHER co-administered: |
LACTIC ACID, D- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
53.35 mg × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15236001/ |
39.76 mmol other, intravenous dose: 39.76 mmol route of administration: Intravenous experiment type: OTHER co-administered: |
LACTATE ION, L- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.44 mg × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15236001/ |
39.76 mmol other, intravenous dose: 39.76 mmol route of administration: Intravenous experiment type: OTHER co-administered: |
LACTIC ACID, D- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls. | 1988 Feb |
|
Cloning of a lactate dehydrogenase gene from Clostridium acetobutylicum B643 and expression in Escherichia coli. | 1990 Dec |
|
Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate. | 1991 May |
|
Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder. | 2007 Jan 15 |
Sample Use Guides
In Vivo Use Guide
Sources: http://labeling.pfizer.com/ShowLabeling.aspx?id=4617
Sodium Lactate Injection, USP 50 mEq (5 mEq/mL) is administered intravenously only after addition to a larger volume of fluid. The amount of sodium ion and lactate ion to be added to larger volume intravenous fluids should be determined in accordance with the electrolyte requirements of
each individual patient. All or part of the content(s) of one (50 mEq in 10 mL) or more vial containers may be added to other intravenous solutions to provide any desired number of milliequivalents of lactate anion (with the same number of milliequivalents of Na+ ). The contents of one container (50 mEq in 10 mL) added to 290 mL of a nonelectrolyte solution or of sterile water for injection will provide 300 mL of an approximately isotonic (1/6 molar) concentration of sodium lactate (1.9%), containing 167 mEq/liter each of Na+ and lactate anion
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26181372
10 mM sodium lactate inhibits activated T cell motility
Substance Class |
Mixture
Created
by
admin
on
Edited
Fri Dec 15 16:10:23 GMT 2023
by
admin
on
Fri Dec 15 16:10:23 GMT 2023
|
Record UNII |
33X04XA5AT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
LACTIC ACID
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
||
|
FDA ORPHAN DRUG |
122098
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
||
|
WHO-ATC |
A07FA01
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
||
|
WHO-VATC |
QP53AG02
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
||
|
DSLD |
1598 (Number of products:7)
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
||
|
WHO-ATC |
G01AD01
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
||
|
CFR |
21 CFR 184.1061
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
||
|
WHO-VATC |
QG01AD01
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
781
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
28358
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
33X04XA5AT
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
114202
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
ALTERNATIVE | |||
|
C45678
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
C76926
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
28393
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200559
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
D019344
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
100000087110
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
1533
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
LACTIC ACID
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
42111
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
DB04398
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
33X04XA5AT
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
Lactic Acid, Citric Acid, and Potassium Bitartrate
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
78320
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY | |||
|
SUB14307MIG
Created by
admin on Fri Dec 15 16:10:23 GMT 2023 , Edited by admin on Fri Dec 15 16:10:23 GMT 2023
|
PRIMARY |
Any of these components may be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
SUB_CONCEPT->SUBSTANCE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|